=NantKwest (NK): final results of a phase I clinical trial of cell therapy platform

NantKwest announces the final results of a phase I clinical trial of the company's aNK cell therapy platform in relapsed hematological malignancies:

The data published in the journal Oncotarget by investigators at Princess Margaret Cancer Centre in Toronto, Canada, demonstrated continuing evidence of safety and efficacy, with an overall response rate of 42% and no evidence of grade 3 or 4 adverse events from the infusions.

• Of the 12 patients in the safety study with relapsed Hodgkin's Lymphoma and Multiple Myeloma, demonstrated durable complete response with single agent aNK therapy, and remain free of disease to date, 10 years and 2 years respectively.
• "Our study was designed to assess safety and preliminary evidence of efficacy in patients with relapsed, refractory hematological malignancies whose disease recurred after autologous hematopoietic cell transplantation (:AHCT). In this heavily pretreated patient population that has a particularly poor prognosis, we demonstrated safety with minimal toxicity and showed preliminary evidence of efficacy, taking advantage of the unique properties of natural killer (NK) cells as an immunotherapeutic agent," said Armand Keating, MD, FRCP(C), Director, Cell Therapy Program.